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Abstract
In 2018, a panel of health economics and meningococcal disease experts convened to review methodologies, frameworks, and 
decision-making processes for economic evaluations of vaccines, with a focus on evaluation of vaccines targeting invasive 
meningococcal disease (IMD). The panel discussed vaccine evaluation methods across countries; IMD prevention benefits 
that are well quantified using current methods, not well quantified, or missing in current cost-effectiveness methodologies; 
and development of recommendations for future evaluation methods. Consensus was reached on a number of points and 
further consideration was deemed necessary for some topics. Experts agreed that the unpredictability of IMD complicates 
an accurate evaluation of meningococcal vaccine benefits and that vaccine cost-effectiveness evaluations should encompass 
indirect benefits, both for meningococcal vaccines and vaccines in general. In addition, the panel agreed that transparency in 
the vaccine decision-making process is beneficial and should be implemented when possible. Further discussion is required 
to ascertain: how enhancing consistency of frameworks for evaluating outcomes of vaccine introduction can be improved; 
reviews of existing tools used to capture quality of life; how indirect costs are considered within models; and whether and 
how the weighting of quality-adjusted life-years (QALY), application of QALY adjustment factors, or use of altered cost-
effectiveness thresholds should be used in the economic evaluation of vaccines.
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Introduction
Invasive meningococcal disease (IMD) caused by Neisse-
ria meningitidis represents a serious public health concern, 
with more than 1 million annual cases estimated to occur 
worldwide [1]. In those with IMD, this normally commen-
sal bacterium (carried asymptomatically in the nasophar-
ynx) is invasive [2]; the precise trigger for this transition 
is unknown. Patients often present with life-threatening 
meningitis or septicemia and may progress rapidly from 
early nonspecific symptoms to unconsciousness and death 
within 24 h [3, 4]. On average, case fatality rates range from 
approximately 10–20%, depending on geographic location 
and meningococcal type, but rates have been observed to be 
as high as 40% in cases of septicemia; these rates are very 
high in comparison with other diseases, making any case 
of IMD an immediate concern [5, 6]. Among those who 
survive IMD, up to 20% may suffer life-altering sequelae, 
such as hearing loss, cognitive deficits, skin scarring, and 
limb amputation [7]. The incidence of IMD is highest in the 
very young (< 1 year of age), adolescents/young adults, and 
the elderly [2, 8]. Seasonal fluctuations in IMD rates may 
occur depending on geographic region, but overall, IMD is 
variable and unpredictable. Some of this unpredictability 
may be attributed to the disease incidence remaining low for 
years at a time until an outbreak is triggered.
Six serogroups (or types) of meningococcus cause the 
majority of IMD: A, B, C, W, X, and Y; these serogroups 
are defined based on differing capsular polysaccharides [9, 
10]. Vaccination and chemoprophylaxis are the only means 
of protection against IMD. Several vaccines are currently 
licensed to protect against disease caused by serogroups A, 
B, C, W, and Y; a vaccine that includes the serogroup X 
antigen is in development [11]. Whether a country chooses 
to implement vaccination with a particular meningococcal 
vaccine depends on many factors, including local epidemiol-
ogy, economic considerations, and expert recommendation 
as well as cost-effectiveness and budget impact. A number 
of recent cost-effectiveness estimates of vaccines targeting 
serogroup B IMD have been outside the range of acceptable 
willingness-to-pay for a quality-adjusted life-year (QALY) 
threshold using standard methods. However, methods vary 
among countries (which can lead to differing conclusions 
among decision-making bodies), and it has been argued that 
standard approaches may not fully capture the impact of 
vaccines [12–16].
In March 2018, a panel of experts met in London, United 
Kingdom, to review methodologies, frameworks and 
decision-making processes for the evaluation of vaccines, 
focusing on IMD. Meeting objectives included discussion 
of vaccine evaluation methods across countries; exploration 
of IMD prevention benefits that are well-quantified using 
current methods, not well quantified, or missing in current 
cost-effectiveness methodologies; and development of rec-
ommendations for future vaccine evaluation methods. This 
report presents an overview of topics discussed, with an 
emphasis on points of consensus and disagreement among 
the panel, as well as recommendations made.
Methods
Panel members included health economists, physicians, 
patient group representatives, and scientists with extensive 
experience in the fields of meningococcal disease and vac-
cine evaluation. Experts were from the United Kingdom, 
Canada, France, Germany, Italy, the Netherlands, Norway, 
Spain, and the United States. This manuscript was developed 
by those attendees who wished to participate as authors.
Meningococcal vaccines: an international 
comparison of decision‑making processes, 
frameworks, and methodologies
Methods to evaluate whether a new vaccine offers an effi-
cient use of resources vary from country to country. A rapid 
evidence assessment of the literature was conducted by 3 
authors affiliated with OHE Consulting Ltd (London, UK) 
to document the evidence used to inform vaccine adoption 
across countries currently and to specifically determine 
whether studies of meningococcal vaccine cost-effectiveness 
have identified and valued various health benefits that could 
be considered [17]. Based on these results, new criteria and 
alternative approaches for, and potential improvements to, 
evaluation methodology were proposed and discussed by 
the panel.
Literature review: rapid evidence assessment
Literature search Three databases were searched for arti-
cles published between January 2005 and November 2016 
containing keywords related to meningococcal vaccines 
and economic evaluation: the National Health Service Eco-
nomic Evaluation Database (UK-based; includes > 16,000 
economic evaluations of healthcare interventions), MED-
LINE (searched via PubMed), and Google Scholar. Of the 
31 articles included in the analysis, most analyzed sero-
group B (MenB) vaccines (12/31) followed by quadriva-
lent conjugate vaccines against serogroups A, C, W, and 
Y (MenACWY; 9/31). High-income countries such as the 
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United Kingdom (5/31), the United States (5/31), and Can-
ada (3/31) produced the most published evaluations; of the 
26 studies that provided full economic evaluations, 7 studies 
deemed vaccination against MenB, serogroup C (MenC), 
or MenACWY to be cost-effective; 5 concluded that the 
evaluated vaccine was not cost-effective; 11 provided mixed 
results (cost-effectiveness varied based on cost per dose); 
and 3 were considered unclear (experts were uncertain 
about criteria for being deemed cost-effective). Across stud-
ies, cost per vaccine dose and the influence of herd protec-
tion (reduction in disease among nonvaccinated individuals) 
were the principal determinants of cost-effectiveness.
Model type and  assumptions Mathematical model choice 
varied among the selected articles, with most studies employ-
ing simple static models. These models can account only 
for direct protection of vaccinated individuals, not for herd 
protection, which is responsible for the majority of cases 
prevented for some vaccines. Other studies used dynamic 
models, which are complex but do account for herd protec-
tion. Several studies used both model types. Herd protection 
in cost-effectiveness analyses is an important consideration, 
especially for adolescent meningococcal vaccination strate-
gies because adolescents are known to have higher carriage 
prevalence (thus being the principal drivers of transmission) 
compared with other age groups.
The studies also varied in terms of the assumptions used 
in their models. Differences in vaccine schedules, age groups 
targeted for vaccination, and dose numbers highlighted the 
complexity of cost-effectiveness evaluations that policy-
makers must consider when deciding whether to adopt a vac-
cine. Assumptions also varied regarding how to measure loss 
of health utility (HU) after contracting a vaccine-preventa-
ble disease. Frequently, HU loss is quantified as QALYs in 
economic studies of IMD. However, consistent estimation 
of HU loss is difficult to achieve because different instru-
ments used to measure quality of life (QoL) capture different 
dimensions (e.g., pain, mobility, emotion) and may therefore 
produce different results. In addition, some HU losses that 
are the result of late-onset sequelae, such as growth plate 
damage or more subtle cognitive effects, may not be cap-
tured if studies are not conducted over longer time periods. 
This issue is particularly pronounced for IMD because HU 
loss among children or adolescents who survived IMD may 
not be captured fully.
Individual HU losses are also widely variable because 
sequelae associated with IMD are diverse, can be multiple, 
and vary in severity. Recognizing these complexities and 
potential deficiencies, the Joint Committee on Vaccination 
and Immunisation (JCVI) in the United Kingdom decided 
that QALYs should be adjusted in situations where health 
benefits may be overestimated or underestimated by models. 
The JCVI has applied a QALY adjustment factor (QAF) of 3 
(relevant QALY gains are multiplied by 3) [18] to long-term 
sequelae associated with MenB IMD, which was employed 
in 2 studies identified in the literature search. Studies of 
HU loss typically address only the patient and his or her 
sequelae, but more recent assessments have included QALY 
losses for caregivers to reflect the wider impact of IMD on 
the network of individuals surrounding the patient [13, 19].
Discounting can be considered the inverse of the interest 
rate applied to future money and health [20] and is meant 
to account for the time horizon used in mathematical mod-
els for vaccine cost-effectiveness. Although use of discount 
rates is standard practice in health economic analyses, dis-
counting methodology has been criticized in vaccine mod-
eling relative to other healthcare interventions because of the 
timing of costs and benefits [21, 22]. Vaccine program costs 
occur early in the model, while the benefits (i.e., reductions 
in disease[s] the vaccine is meant to prevent) may not be 
evident for several years; thus, the benefits of vaccination 
are more heavily discounted compared with the costs, mak-
ing vaccination appear less favorable compared with health 
programs where benefits are realized quickly.
Discount rates may be applied equally or differentially 
to costs and benefits. Applying a lower discount rate to 
benefits compared with costs may be done to account for 
the growing value of health effects [23]. Application of dif-
ferent discounting rates can lead to wide variation in the 
incremental cost-effectiveness ratio (ICER) provided by a 
model [24]. For example, when equal discount rates of 4% 
were applied to an analysis of human papilloma virus (HPV) 
vaccination in the Netherlands, the ICER was estimated at 
€101,700; however, applying discount rates of 4% and 1.5% 
to costs and health effects, respectively, the ICER decreased 
to €29,900 [24]. Regarding IMD vaccination specifically, 1 
study found that application of a 5% discount rate compared 
with a 0% discount rate led to an ICER increase of 419% 
for a quadrivalent meningococcal conjugate vaccine [25]. 
Discounting as a principle is widely accepted. However, 
application of differential discounting varies by country and 
is the subject of ongoing debate [26]. Nevertheless, more 
countries are opting to use differential discounting in their 
cost-effectiveness analyses [21].
The use of differential discounting in models also var-
ies by country. Although more countries are moving toward 
differential discounting, most still use equal discount rates. 
Germany uses both types of discounting and compares 
results between them, whereas the United Kingdom applied 
a 3.5% discount rate equally to costs and benefits (although 
this policy is being reconsidered regarding vaccines and has 
since been reduced to 1.5% for all health costs and ben-
efits) [27–29]. Panel members concluded that there is no 
straightforward answer to the question of whether differ-
ential discounting better reflects the value of vaccines rela-
tive to equal discounting. If used, differential rates should 
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be tested in sensitivity analyses to inform decision-makers 
about the relative importance of selected discount rates to 
the outcome. Panel members also suggested that additional 
discussion is needed to address whether vaccines specifically 
should merit application of differential discounting rates or 
whether all health technologies with a lengthy benefit time 
horizon should benefit from differential discounting.
Incremental analyses are used to estimate additional 
costs and benefits beyond a specified intervention and may 
be beneficial when evaluating differences in vaccine dose 
schedules or targeted age groups. Incremental analyses and 
use of lifetime timescales remain well-accepted strategies for 
economic evaluation of vaccines. For instance, in an evalua-
tion of MenC vaccination in the Netherlands, incrementally 
comparing a 3-dose series in infancy to a single toddler dose 
at 14 months of age, approximately 2 extra deaths were pre-
dicted to be averted by implementing the 3-dose schedule, 
with the single-dose schedule averting the vast majority of 
20 expected deaths. This suggested that implementation of 
an infant series would not be cost-effective, and a single-
dose schedule after the first birthday was chosen [30]. In 
the United Kingdom, a separate internal analysis indicated 
that all schedules were cost-effective, and that country chose 
to use a 3-dose infant MenC schedule with a catch-up cam-
paign to 21 years. Incremental analyses may also be used 
to assess whether adjustments to existing schedules will be 
cost-effective, although the choice of comparator is complex 
in the context of highly effective programs where little ongo-
ing disease remains.
Most studies identified in the literature search (61%) 
attempted to conduct analyses from the societal perspective, 
which seeks to account for all costs and benefits irrespective 
of whom they are associated with (however, most identi-
fied analyses were not able to capture all indirect benefits 
comprehensively). This perspective encompasses the indi-
rect costs of IMD that include economic productivity losses, 
premature death, inability to work, and special educational 
or social welfare needs for children with cognitive or sensory 
sequelae and their families. Such indirect costs are important 
to consider when evaluating a preventive health intervention, 
such as vaccination.
Similar to observations regarding models and discount-
ing, the preferred analysis perspective for cost-effectiveness 
evaluations of vaccines varies from country to country. 
Although selection of perspective is related to the goal of 
the evaluation (e.g., a health ministry aiming to optimize 
public health impact from a fixed budget allocation), experts 
suggested that conducting the most comprehensive analysis 
possible using the widest perspective should benefit both 
decision-making bodies and the public.
Current models for vaccine evaluation include static and 
dynamic models, with the latter capturing possible herd 
effects of vaccination programs. Different countries prefer 
different models, but experts suggested both model types 
could be used and results compared to provide a more com-
prehensive view of vaccine cost-effectiveness. Dynamic 
models must be used to appropriately capture all benefits 
for vaccines that prevent transmission as well as disease. 
Regarding meningococcal vaccination, additional studies 
will be required to discern whether herd effects play a role 
in the effectiveness of MenB vaccination programs, as has 
been demonstrated for vaccines targeting other serogroups 
[31–34]. A cluster-randomized study is currently under way 
in Australia to investigate MenB-4C  (Bexsero®, 4CMenB; 
GlaxoSmithKline Vaccines, Srl, Siena, Italy) for effects on 
carriage, and by extension, transmission [35]. Results from 
this study coupled with an adolescent study under way in 
the United Kingdom [36] may elucidate whether adolescent 
MenB vaccination programs could produce a herd effect.
The choice of analytic time horizon used in models is also 
subject to debate; panel members suggested that a cohort 
lifetime horizon seems to be preferred in vaccine cost-effec-
tiveness analyses, but payers may apply a shorter horizon. If 
a shorter horizon is included, such as with a cross-sectional 
approach useful for evaluating budget impact and health at 
the population level, relevant outcomes may not be captured. 
However, extending the horizon long into the future may 
lead to increasing uncertainty surrounding estimates [37].
Country comparisons: methodology for health technology 
appraisal and decision‑making
Evidence and procedures used to evaluate health technolo-
gies vary by country. The OHE consulting report docu-
mented methodology and criteria used by 7 countries (Aus-
tralia, France, Germany, Italy, Japan, New Zealand, and 
the Netherlands; Table 1) to inform policy decisions sur-
rounding vaccine adoption, which included interviews with 
country-specific experts. Experts were those individuals 
with a deep knowledge of the processes followed for vac-
cine adoption in that country and/or direct understanding of 
formulary development or vaccine-related reimbursement 
decisions. Countries were selected if they had conducted an 
economic evaluation of a MenB vaccine or if their evidence 
base and decision-making processes were advancing rapidly 
(the United Kingdom was not included in the analysis based 
on the original scope of the project).
Expert interview results Across all 7 countries, clinical out-
comes and the targeted age group are formally required to 
be considered in decision-making. All countries have evalu-
ated HU loss measured by QALYs, although in Germany 
this is part of an economic evaluation that may not always 
be required; in Japan, this type of evaluation is uncommon 
and informal (i.e., the evaluation is not normally part of the 
analysis but has been considered in particular cases). Like-
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wise, the assessments of cost-effectiveness and disease bur-
den, severity, and sequelae are formally considered in all 
countries except Japan, although they remain key criteria in 
Japan’s decision-making. France and Japan do not require 
consideration of the cost offset per patient to the health-
care system, but Japan does commonly and informally con-
sider this parameter. Consideration of public preferences 
and innovation aiding vaccine development, although not 
required, is commonly considered in Japan but not in any 
of the other countries. The concept of equity, which encap-
Table 1  Methodology of vaccine health technology appraisal
CTV Technical Vaccination Committee, DoH Department of Health, G-BA Federal Joint Committee, MHLW Ministry of Health, Labor, and 
Welfare, PBAC Pharmaceutical Benefits Advisory Committee, PHARMAC Pharmaceutical Management Agency, QALY quality-adjusted life-
year, RIVM National Institution for Public Health and Environment, STIKO Standing Committee on Vaccination
Country Health technology appraisal method
Australia Decisions to approve vaccine reimbursement rest with the Department of Health (DoH) within the federal government. The 
Pharmaceutical Benefits Advisory Committee (PBAC) provides guidance to the DoH regarding whether to include the vaccine 
in the Pharmaceutical Benefits Scheme or the National Immunisation Program. The Economic Sub-Committee of the PBAC is 
responsible for evaluating and interpreting economic analyses of health technologies; this guidance, combined with additional 
input from the Australian Technical Advisory Group on Immunisation and another independent group (frequently academic 
health economists) is used for comprehensive assessments of vaccine applications. Uncertainty surrounding economic evalua-
tion outputs is acknowledged and clearly considered in final decision-making
France Vaccination policy in France is developed by the Ministry of Health based on recommendations from the Technical Vaccination 
Committee (CTV), an independent expert committee that devises immunization strategies and provides advice—including eco-
nomic evaluations—on new vaccines. The CTV provides pharmacoepidemiologic evidence, disease modeling, and assessment 
of vaccination strategies during dossier evaluation. If deemed necessary by the CTV, vaccine cost, program cost, affordability, 
or financial sustainability may also be evaluated. After consideration of evidence from the CTV and the Commission for Trans-
parency, which determines the impact of the vaccine on public health services, the final decision regarding integration into the 
national immunization schedule is made by the High Authority of Health
Germany In Germany, vaccination recommendations at a national level are made by the Standing Committee on Vaccination (STIKO). 
Based on the STIKO recommendations, the Federal Joint Committee (G-BA) decides whether a vaccine is included in the 
mandatory service of statutory health insurances. STIKO recommendations principally rest on a risk–benefit assessment that 
includes a number of criteria described in a standard operating procedure. The criteria list comprises, among others, efficacy, 
effectiveness, safety, number needed to vaccinate, and expected population-level effects. Economic analyses are not obligatory 
but may be considered when based on independently funded models. QALYs can be used as a summary measure of health 
outcome, although the STIKO and the G-BA have not set a cost-per-QALY threshold
Italy The recommendation of health technologies in Italy is conducted at the national level, but because of a highly decentralized 
national health service, decisions by the National Ministry of Health are nonbinding on local health authorities. The National 
Vaccine Prevention Plan issued by the Ministry of Health provides guidance and recommendations at the national level. 
However, decisions surrounding vaccine adoption may differ from region to region because some vaccines are mandatory at a 
national level and administration of others is determined within each region. Italian guidelines use cost-effectiveness analyses 
and QALYs as the foundation of economic evaluations
Japan Regulation of vaccines and other heath technologies requires coordination between the Japanese Ministry of Health, Labor, and 
Welfare (MHLW) and the Pharmaceuticals and Medical Devices Agency. In 2009, the Infectious Disease Sectional Committee 
made a recommendation to the government leading to inclusion of economic evaluations in decisions regarding vaccine adop-
tion. The Health Science Council, also within the MHLW, is responsible for considering cost-effectiveness, but this evaluation 
is not required
New Zealand The Pharmaceutical Management Agency (PHARMAC) in New Zealand decides the public funding of pharmaceutical products, 
including vaccines. PHARMAC evaluates 4 parameters when assessing a product: need, health benefits, costs and savings, and 
suitability. In addition, the agency considers 3 levels of impact on society: personal, health sector, and wider society. Informa-
tion also considered for vaccine efficacy modeling are degree and length of protection, age at administration, dosing schedule 
adherence, adverse reactions, possible loss of potency due to cold chain issues, and herd protection. The final decision for vac-
cine adoption rests with the Minister of Health based on the PHARMAC evaluation
The Nether-
lands
The Dutch Ministry of Health decides whether to add a new vaccine to the national immunization plan and/or the “positive 
list” based on guidance from a Health Council subcommittee and the Drug committee, respectively. The Health Council 
subcommittee considers 2 assessments, the first by the National Institution for Public Health and Environment (RIVM), and 
the second, often by a university. One main criterion for evaluation are economic analyses. The Drug committee conducts 1 
assessment, using materials submitted by the vaccine manufacturer, which must include a cost-effectiveness analysis. Recently, 
a new policy has been implemented to streamline the evaluation process to include only the RIVM and manufacturer-sponsored 
assessments. Vaccine evaluation is prioritized by the Ministry of Health, based mostly on severity and health burden of the 
disease in question, whereas evaluation by the Drug committee for inclusion in the positive list is not prioritized but initiated by 
the manufacturer. Recommendations of the Health Council subcommittee and Drug committee include information about the 
degree of uncertainty in the analyses and how this uncertainty may influence the robustness of the outcomes; a vaccine is not 
introduced if uncertainties are too influential or the severity is not considered high enough
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sulates efforts to reduce inequality in access to healthcare, 
was considered a key component of decisions in Australia, 
Japan, and New Zealand, but is not formally considered. 
Consideration of “peace of mind” benefits was uncommon.
Meningococcal vaccine recommendations differ by 
country, with the MenC vaccine included in the national 
immunization schedule in Australia, France, Germany, and 
Italy, but not New Zealand or Japan. MenC vaccine was 
recommended in the Netherlands until the spring of 2018, 
when MenACWY was recommended instead [38]. The Men-
ACWY vaccine is also included in the national immuniza-
tion schedule in Italy but not in Japan, Australia, France, 
Germany, or New Zealand. Among the 7 countries reviewed, 
MenB vaccination is routinely recommended only in Italy 
for children ≤ 1 year of age.
Adding to the country-specific variability in vaccine eval-
uations and approvals, individual countries will negotiate 
vaccine prices with manufacturers based on the laws and 
guidelines specific to that country. If a manufacturer has 
additional drugs in its portfolio in a given country, negotia-
tions may include adjustment of other drug prices to pro-
vide more financial leeway for the vaccine price negotia-
tion. Some countries, such as New Zealand, operate on fixed 
budgets for pharmaceuticals, including vaccines, whereas 
others do not.
Measuring disease burden
Based on the OHE consulting report, disease burden is a 
crucial factor considered by 6 of the 7 countries when eval-
uating a vaccine for inclusion in a national immunization 
program. Burden of disease and its sequelae can be clinical 
(incidence, morbidity, mortality), economic (costs of the 
disease and sequelae), or humanistic (QoL). Determination 
of true incidence relies on the accurate capture of case num-
bers, but trends in incidence may also make use of sentinel 
cases (cases from selected reporting sites). For the purposes 
of economic evaluations, health-related burdens (morbid-
ity and mortality) are commonly quantified as QALYs or 
disability-adjusted life-years. Broader and narrower aspects 
of burden included in the QALY will influence the estimate. 
For meningococcal disease, burden may differ depending 
on whether a model incorporates acute and/or long-term 
QALYs and QALYs from the survivor’s and the caregiver’s 
perspective. The OHE consulting report recommends rig-
orous assessment of the data used to generate QALY loss 
estimates and determination of whether the estimates can be 
transferred across different disease contexts (e.g., different 
countries).
Panel members discussed possible factors to consider in 
vaccine evaluations to achieve a comprehensive view of the 
burden of meningococcal disease. In the Netherlands, mor-
tality is the main factor considered in burden estimates for 
vaccine evaluations, whereas Germany focuses on hospitali-
zation, long-term disability, and mortality. France consid-
ers the severity of the disease itself to be most important, 
whereas QoL is viewed as a less important factor. Italian 
authorities place more focus on morbidity than mortality, 
viewing costs related to social burden and use of national 
health service resources (including possible need for life-
long services) as main contributors to decision-making. The 
panel suggested that subsequent comorbidities triggered by 
IMD is an overlooked component of disease burden, given 
the potentially lifelong multiple sequelae experienced by 
survivors.
A critical factor in determining whether to adopt a vac-
cine lies with the accurate quantification of disease bur-
den, which directly influences the predicted impact of the 
vaccine program. For some vaccine-preventable diseases, 
such as HPV and rotavirus, the disease burden is relatively 
predictable.
In contrast, IMD is highly unpredictable over time and 
panel members agreed that a key challenge is how to incor-
porate that unpredictability into a mathematical model. 
Using MenC vaccination in the United Kingdom as an 
example, disease incidence decreased after vaccine imple-
mentation as expected, but the panel agreed that predicting 
the true annual incidence in the absence of the vaccination 
program would have been impossible. The consensus frame-
work for disease modeling is to assume a steady-state annual 
incidence in the absence of vaccine intervention. Thus, vac-
cination benefit is measured as the predicted reduction in 
cases. In the case of IMD, disease incidence can remain 
low for many years until the emergence and expansion of 
hyperendemic virulent clones. Models are unable to predict 
when this may occur. Outcomes also depend on the selected 
time horizon; years of low incidence can dominate modeling 
outputs even if hyperendemic periods may be a public health 
concern; thus, the stochastic nature of IMD calls into ques-
tion whether the same models should be used for predictable 
and unpredictable vaccine-preventable diseases. Experts 
agreed that vaccines for diseases with epidemic potential 
should be evaluated differently depending on disease pre-
dictability, although the panel could not identify an existing 
methodology to address this.
Experts also agreed that IMD outbreaks vary in sever-
ity depending on serogroup or clonal complex, which may 
translate to more severe sequelae that may not be captured 
and quantified in analyses depending on the data sources 
used. The panel agreed that evaluation of aggregate IMD, 
rather than evaluation of burden associated with a specific 
meningococcal serogroup, is suitable for cost-effectiveness 
models, similar to analyses performed for aggregate pneu-
mococcal disease rather than analysis by specific pneumo-
coccal serotype. Unlike pneumococcal disease, for which 
herd effects are now well known, if data are not available to 
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inform whether a vaccination program produces herd protec-
tion, the unpredictability of transmission effects adds to the 
uncertainty of the vaccine impact. These issues continue to 
present challenges in vaccine cost-effectiveness studies, and 
experts indicated a need to identify strategies to incorporate 
these uncertainties into evaluations.
Capturing burden of disease requires more than simply 
capturing case numbers. The burden of IMD is likely to be 
underestimated in economic analyses, because QALYs may 
not reflect all types of burden (e.g., burden for the patient, 
the caregiver, individuals with multiple sequelae rather than 
a single sequela, pediatric versus adult populations). The 
QoL profiles used to generate QALYs are measured using 
patient reported outcomes such as the EQ-5D and other tools 
such as time trade off, the visual analogue scale and the 
standard gamble method [39]. These instruments measure 
and apply values to attributes of health, including anxiety. 
However, the panel did express concern regarding the ability 
of these instruments to capture infant health status based on 
proxy respondents, such as parents. The panel also ques-
tioned the evidence base estimating QALY loss later in life 
and whether such evidence is adequately included in cost-
effectiveness analyses.
When considering input parameters that should be 
included in cost-effectiveness models, experts suggested that 
health outcomes (e.g., sequelae, mortality), accurate assess-
ments of infant QoL, and impact on caregivers (during acute 
disease and later in life) should be incorporated. Attempting 
to measure all possible effects of IMD on QoL is difficult 
because impacts on caregivers decrease as social distance 
from the IMD survivor increases [40]. However, focusing 
on the IMD survivor and his or her immediate family would 
likely be sufficient to account for QoL-based QALY loss 
associated with an IMD case. In addition to QALYs, ele-
ments such as peace of mind (decreased anxiety) may merit 
inclusion in models, although evidence of this in relation to 
vaccine-preventable diseases is currently limited.
Consideration of vaccine benefits
Discussions to develop a list of vaccine benefits that should 
be included in current meningococcal vaccine evaluations 
centered on analysis perspective, inclusion of indirect 
benefits, and the ease with which various benefits may be 
measured.
Before addressing benefits, the panel first discussed 
inclusion of indirect costs in meningococcal vaccine eval-
uations. These factors are important but typically not con-
sidered because of the difficulty associated with measuring 
them. Examples of indirect costs include lost productivity 
of the survivor (if of working age) or caregiver, and lower 
educational attainment by younger survivors. Lost produc-
tivity may be larger for the IMD survivor in the workforce 
as opposed to a retired individual, but it is important to 
note that the elderly population still engages in economic 
activity (e.g., volunteering, informal care) that is other-
wise lost during illness with IMD. Lost productivity may 
be a crude proxy for societal costs, especially for a disease 
such as IMD that predominantly affects children. Future 
earnings potential for children once they reached working 
age would be dramatically reduced (depending on the dis-
count rate used), potentially leading to equality issues if 
only productivity losses were used as a proxy for societal 
costs.
Although many countries do not currently consider 
indirect costs, experts agreed that indirect costs should be 
included in evaluations, not only for those vaccines that tar-
get IMD, but also for vaccines in general. Indirect costs may 
be considered in the form of a societal cost-effectiveness 
analysis. Multicriteria decision analysis (MCDA) is an alter-
native method of health technology assessment that can be 
applied to vaccines. This method involves defining the crite-
ria that are important to recommendation or reimbursement 
decisions, scoring the vaccine on each criterion, assigning 
a weight to each criterion specified, and constructing an 
overall vaccine score. Decisions are made by comparing 
the score to some prespecified threshold or to the scores 
for other candidate vaccine or nonvaccine interventions. 
Although MCDA is evolving to become more rigorous, it 
is often criticized for the ad hoc manner in which prefer-
ence weights are assigned and for the unintentional double-
counting of overlapping criteria.
One major vaccine benefit is herd protection. In the 
example of MenC vaccination in the United Kingdom, herd 
protection was not initially predicted as a benefit following 
implementation of the vaccine, but it was later shown to have 
played an important role in the overall effectiveness of the 
MenC program. Herd effects are relatively straightforward 
to measure after vaccine implementation but are difficult to 
predict and therefore to model accurately beforehand. The 
size of herd effects from MenB vaccination in adolescents is 
not yet clear, but additional studies designed to address this 
issue are currently under way.
Numerous indirect benefits may be considered in cost-
effectiveness analyses of meningococcal vaccines conducted 
from a societal perspective (Table 2). Among these, labor 
force benefits and educational benefits are more easily rec-
ognizable, but less well-known benefits, such as increased 
equity and decreased nosocomial infections, are also evident. 
Cost-effectiveness analysis allows comparison of interven-
tions (with different success indicators) within and between 
sectors. However, this advantage may be mitigated by poten-
tial ethical issues stemming from the assignment of greater 
value to reducing the mortality or morbidity risks of high-
earners compared with low-earners (all else being equal) 
[41].
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The ability to quantify and monetize indirect benefits of 
vaccination plays a substantial role in producing accurate 
evaluations of vaccines for adoption. Panel members agreed 
that indirect benefits should always be considered in vaccine 
evaluations, but uncertainty still remains surrounding the 
availability of information needed to fully consider these 
types of benefits. Including the wider societal benefits of 
preventing ill health could ultimately lead to higher willing-
ness-to-pay for health interventions in general.
Vaccine benefits not commonly considered
In addition to the clinical and economic benefits offered by 
meningococcal vaccines, less frequently considered benefits 
may be important factors in determining whether to add a 
vaccine to a national immunization schedule (Fig. 1). For 
example, vaccination may provide peace of mind (decreased 
anxiety) to patients (and caregivers) who benefit from know-
ing they have reduced their risk of contracting a potentially 
fatal disease. Peace of mind is difficult to measure because, 
among those who experience it, peace of mind accrues to 
healthy individuals rather than to those with the disease, and 
is not usually included in base/reference cases in standard 
economic evaluations of vaccines. It is not clear whether 
or how decision-makers should take into account healthy 
individuals’ concerns regarding the risk of severe illness 
for themselves or their family members. Stated preference 
research may aid health economists in understanding how 
people assign value to this type of intangible benefit.
In a qualitative study conducted by 2 panel members and 
their colleagues, 21 UK adults participated in 4 rounds of 
semistructured interviews to identify factors they considered 
Table 2  Indirect benefits of meningococcal vaccination programs in a cost-effectiveness analysis from a societal  perspectivea
a Indirect benefits include non-health benefits that follow from reduced incidence of meningitis; they also include downstream health benefits
Benefit Description
Economic and financial
Labor force Increased productivity and tax revenues
Education Increased school attendance leading to better education and greater potential productivity as an adult
Medical care Lower use of healthcare resources
Outbreak control Lower expenditure on outbreak response
Indirect costs Lower mortality associated with meningococcal disease (cause of death shifts to other diseases with different 
associated costs)
Health
Herd effects Reduction in disease incidence among unvaccinated individuals due to decreased transmission of the pathogen
Comorbidities Lower risk of developing secondary comorbidity associated with primary disease
Nosocomial infections Lower risk of acquiring additional infection while hospitalized for primary disease
Antimicrobial resistance Reduced incidence of resistant infections in the population due to reduced reliance on antibiotics
Health systems Less strain on health systems, increasing capacity to treat other conditions
Societal
Family members/caregivers Lower burden (financial, psychological) on those caring for survivors
Leisure Improved quality of leisure time due to better health
Peace of mind Less anxiety at the individual and societal level about contracting meningococcal disease
Equity Increased socioeconomic equity and increased access to preventive care for disadvantaged groups
Political implications Lower infant/child mortality is correlated with stable political systems
All countries
Clinical outcomes
Cost-effectiveness (but often informally)
Most countries
Disease burden
National health system priorities
Some countries
Equity
Budget impact
Few/none
Peace-of-mind benefits
Public/societal preferences
Fig. 1  Decision criteria used in meningococcal vaccine evaluations. 
Criteria used in vaccine evaluations vary by country. Examples are 
shown for those that are more or less frequently considered
Economic evaluation of meningococcal vaccines: considerations for the future 
1 3
important to vaccine decision-making [42]. Five factors 
emerged as dominant: age group, disease severity, how com-
mon the disease is, effect on caregivers, and social group 
(advantaged/disadvantaged). Vaccine side effects, herd 
effects, decreased disease incidence, and peace of mind were 
not considered as important. A subsequent focus group indi-
cated that vaccination may be viewed by some as more a 
matter of accepted routine than for seeking peace of mind. 
Although these findings are informative, additional studies 
are needed to confirm these observations before clear con-
clusions may be reached.
Related to peace of mind is utility in anticipation, which 
describes the provision of the peace of mind benefit to 
vaccinated individuals and their caregivers starting at the 
moment of vaccination, when they know they have protected 
themselves from disease [43]. Earlier vaccination increases 
the duration of the utility of anticipation benefit. However, 
standard economic approaches do not include this param-
eter but rather count the benefits from the moment of illness 
occurring. Arguably, current economic evaluation methodol-
ogy omits the additional benefit of anticipation that occurs 
before illness and therefore underestimates total vaccine 
benefits. Moreover, including peace of mind benefits only 
for the proportion of the population predicted to develop the 
disease potentially underestimates peace of mind for all who 
are vaccinated against something they fear, whether or not 
those individuals would have developed the disease. A more 
comprehensive value of vaccine benefits should include pre-
vented health loss from time of illness onset plus the utility 
in anticipation benefit that initiates at vaccination.
Weighting of quality‑adjusted life‑years
QALY weights based on societal preferences are not typi-
cally applied in vaccine evaluations. Many decision-making 
bodies consider all QALYs to be of equal social value, but 
there is some evidence to suggest that society would prefer 
to weight QALYs differentially based on severity of illness 
and the age of the affected population (i.e., there is a greater 
willingness to pay for interventions that prevent QALY loss 
in severe disease rather than in mild disease and in infants 
rather than adults) [44–49]. Conversely, ethicists may not 
agree with such societal preferences; for example, in the 
United Kingdom, a policy statement for responding to pan-
demic influenza states that everyone matters equally (i.e., 
equal importance is placed on the lives of the elderly as the 
lives of children) [50].
Although societal preferences indicate disease severity 
should be considered in vaccine evaluations, the additive 
nature of a QALY (i.e., preventing small losses in QoL in 
many people can be worth as many QALYs as preventing 
life-long disability in few people) may require that sever-
ity be prioritized through a separate weighting. In addition, 
studies conducted to assess public preferences for preven-
tive versus curative interventions indicate greater value is 
placed on preventive treatments, especially for more severe 
and possibly life-threatening illnesses [51–53]. These studies 
provide support for the possible public perception of menin-
gococcal vaccines as highly valuable because they meet the 
criteria outlined above: meningococcal vaccines are preven-
tive, protect against a severe, life-threatening disease, and 
offer protection to targeted vulnerable populations.
Some members of the group agreed that QALY weight-
ing could be a useful way to reflect the preference of society 
in vaccine evaluations, although the influence of weighted 
QALYs on decision-making is often unclear to those not 
participating in decision-making processes, suggesting a 
need for increased transparency. For example, the JCVI 
assigned an adjustment factor of 3 to QALYs determined 
for long-term sequelae due to IMD, though the rationale 
for this was not published at the time. As an alternative to 
QALY weighting, decision-makers could explore alteration 
of the cost-effectiveness thresholds [54] for vaccine adop-
tion, giving particular consideration to meningococcal vac-
cines because of the severity and consequences of IMD in 
pediatric populations.
Peace of mind benefits
Quantifying peace of mind is complex, and uncertainty per-
sists regarding how and when to include such a parameter 
in vaccine evaluations. The panel debated whether peace of 
mind is essential to cost-effectiveness analyses or whether its 
influence is insufficient to sway outcomes. To benefit from 
peace of mind, a patient or caregiver must first be aware that 
a threat exists. Some parents may be unfamiliar with the 
incidence rates and clinical consequences of meningitis and 
some may have an exaggerated perception of the likelihood 
of contracting IMD. Conversely, meningococcal vaccina-
tion may potentially allay a parent’s fear of meningitis each 
time his or her child develops a fever or nonspecific symp-
toms that overlap with early-stage IMD, but this remains a 
matter of debate. Whether vaccination could prevent inap-
propriate use of healthcare resources due to peace of mind 
benefits is unclear, but the costs saved by preventing diver-
sion of healthcare resources could potentially be quantifi-
able, although they are not factored into cost-effectiveness 
analyses.
Studies using revealed preferences and evaluation of 
willingness-to-pay for meningococcal vaccines are possible 
strategies to understand how much importance society places 
on preventing IMD. However, using propensity to pay as a 
methodology would need to account for equity issues related 
to wealth and perception of payment for health, rather than 
viewing the stated propensity in isolation. Panelists also 
discussed surveying parents who sought medical care for 
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their child for suspected meningitis as a possible strategy to 
obtain estimates of unnecessary resource use. Overall, how 
to quantify and include peace of mind is worth additional 
exploration, but panelists did not agree on its usefulness.
Are current tools sufficient, or do we need to use 
adjustment factors?
As noted above, to account for underestimation of true 
health benefits in models of MenB cost-effectiveness, the 
JCVI introduced a QAF of 3 for long-term or lifelong seque-
lae (the QAF was not applied to short-term losses). Factors 
influencing the QAF included difficulty capturing loss of 
QoL in IMD survivors, especially the youngest individuals, 
the innovative nature of the MenB vaccine being evaluated, 
and wider societal preferences. When comparing modeling 
outputs using a QAF of 3 versus no QAF for a 2-, 3-, 4-, 
and 12-month MenB vaccination schedule, the number of 
QALYs gained increased substantially whereas cost per 
QALY gained and vaccine price for cost per QALY gained 
(threshold set at £20,000) decreased. Essentially, applica-
tion of the QAF rendered the vaccine cost-effective at £3 
per dose [12].
Panel members discussed whether the current tools for 
measuring disease burden and vaccine benefits are sufficient 
to provide accurate analyses and whether adjustment factors 
should be used more widely in the assessment of vaccines. 
However, there was no clear consensus on the use of the 
QAF.
Some panelists viewed the QAF as an arbitrary, nontrans-
parent adjustment that should not supplant addressing the 
underlying issue of the imperfect nature of QALYs used in 
cost-effectiveness models. The assigned value of the QAF 
(× 3) is also a subject of debate. Some of the panelists sug-
gested that cost-effectiveness thresholds could be increased 
as an alternative to application of the QAF. In addition, 
consideration of the QAF encompassing the value of vac-
cine innovation was viewed by some to be a parameter that 
should instead be factored into the cost-effectiveness thresh-
old. Although increased thresholds could potentially be 
applied for only certain types of interventions with specific 
characteristics (such as vaccines), they may cause special 
treatment to be given to new interventions (compared with 
displaced existing interventions with similar characteristics) 
as an unintended consequence. Additionally, flexibility to 
make adjustments to the threshold may result in multiple 
thresholds being used to evaluate cost-effectiveness of dif-
ferent health interventions.
Other panel members suggested the QAF could be used 
effectively because it is not applied universally but is con-
sidered only for specific situations, such as IMD vaccines; 
the sense of urgency associated with efforts to prevent 
IMD could justify use of the QAF. Moreover, the JCVI had 
already noted that application of the QAF was equivalent 
to raising the cost-effectiveness threshold to £45,000 [18]. 
Nevertheless, a clear process should be implemented to 
determine in which situations the QAF should be applied.
Factors that may be difficult to capture using current cost-
effectiveness analysis tools include equity, political factors, 
innovation, and other generally intangible parameters. This 
discussion highlighted the remaining uncertainty surround-
ing how to optimize the assessment of vaccine cost-effec-
tiveness. An additional review of tools currently used to 
measure disease burden is needed.
Consistency and transparency in vaccine 
decision‑making
During evaluation of a vaccine for adoption, numer-
ous variables are considered that range in transparency 
and consistency. Those variables that are more consist-
ent or predictable are frequently more transparent and 
are often included in formal considerations of vaccines. 
Such variables are more easily quantifiable and include 
clinical outcomes, severity of disease, burden of disease, 
and associated sequelae. Factors that are less consistent 
tend to be less transparent and more difficult to quantify. 
These include equity and public preference, which are 
encompassed in the public’s understanding of the impact 
of disease on their own lives.
As demonstrated in the OHE consulting report on vac-
cine decision-making processes in 7 countries, substan-
tial variability exists in evidence considered and meth-
ods used to inform vaccine adoption. Panel members 
discussed advantages and disadvantages associated with 
increasing the consistency and transparency of vaccine 
decision-making.
Economic evaluation models are generalizable and the 
results should be transferrable across countries with simi-
lar meningococcal epidemiology; panelists agreed that a 
core set of principles for a single model could be devel-
oped. However, there are issues particular to each country 
that complicate universal application, such as variable 
disease burdens, changing epidemiology, differences in 
disease surveillance systems, disparate healthcare laws, 
differential budget constraints, societal preferences, and 
political factors, all of which influence consistency in 
evaluating vaccines for adoption. As outlined by the 
World Health Organization guidance on the standardiza-
tion of economic evaluations for vaccine programs [55], 
such a model could be customizable per country-specific 
inputs, leading to a consistent evaluation process that pro-
duces appropriately variable (for each country) outcomes.
Experts agreed that transparency in decision-making is 
beneficial to the public and should be implemented wherever 
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possible. The panel suggested that making mathematical 
models available for critique may both increase transpar-
ency and improve any given model [56]. Inclusion of stake-
holder input into the evaluation process may also enhance 
transparency. An example is the UK JCVI, which includes 2 
lay representatives who are interviewed and chosen to bring 
nontechnical insight into vaccine policy and consequent 
public health impact. However, experts noted that involve-
ment of patient groups in vaccine decision-making may be 
complicated, but patient groups that have expert knowledge 
can bridge the gap between patients/families and experts, 
and could play a role in advising decision-makers. Addi-
tional assessments of the value of patient/public involvement 
are needed.
Conclusions
Panel experts in health economics and meningococcal dis-
ease met in 2018 to review current information on menin-
gococcal vaccine cost-effectiveness evaluation strategies. 
Fundamentally, the unpredictability of IMD hinders a pre-
cise evaluation of meningococcal vaccines for inclusion 
in national immunization programs; however, transparent, 
dynamic, broad, and flexible health-economic models do 
provide the necessary evaluative tools for decision-making 
bodies such as JCVI to evaluate cost-effectiveness of vac-
cines. This can in turn inform technical committees regard-
ing the value of adding new vaccines into routine schedules. 
Priorities for future discussion are enhancing consistency of 
frameworks for evaluating outcomes of vaccine introduction; 
reviewing existing tools used to capture QoL; developing a 
modeling framework to address the unpredictability of IMD; 
determining how indirect costs and benefits (i.e., carer health 
benefits) are considered within models; and assessing how 
the weighting of QALYs and cost-effectiveness thresholds 
may affect the use of adjustment factors such as the QAF.
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